Found 9 results
[ Author(Asc)] Keyword Title Type Year
Filters: Author is Andreas du Bois  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A. du Bois, Belau, A., Wagner, U., Pfisterer, J., Schmalfeldt, B., Richter, B., Stähle, A., Jackisch, C., Lueck, H. J., Schröder, W., Burges, A., Olbricht, S., Elser, G., and Group, A. Gynaekolog, A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8), Gynecol Oncol, vol. 96, pp. 444-51, 2005.
A. du Bois, Luck, H. J., Meier, W., Adams, H. P., Möbus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schröder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., Kuhn, W., Pfisterer, J., and Group, A. Gynakologi, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J Natl Cancer Inst, vol. 95, pp. 1320-9, 2003.
A. du Bois, Meier, W., Luck, H. J., Emon, G., Möbus, V., Schröder, W., Costa, S., Bauknecht, T., Olbricht, S., Jackisch, C., Richter, B., and Wagner, U., Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer, Ann Oncol, vol. 13, pp. 251-7, 2002.
A. du Bois, Schmalfeldt, B., Meier, W., Sehouli, J., Pfisterer, J., OVAR, A. Gynaekolog, Cancer, A. G. O. Study Grou, and Onkologie, N. Gesellscha, Ovarian cancer–can intraperitoneal therapy be regarded as new standard in Germany?, Int J Gynecol Cancer, vol. 16, pp. 1756-60, 2006.
A. du Bois, Kristensen, G. B., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. Oliver, Merger, M., and Harter, P., Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer., J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
A. du Bois, Neijt, J. P., and Thigpen, J. T., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?, Ann Oncol, vol. 10 Suppl 1, pp. 35-41, 1999.
A. du Bois, Quinn, M., Thigpen, T., Vermorken, J. B., Åvall-Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Högberg, T., Kaye, S. B., Kitchener, H. C., Kristensen, G. B., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A. M., Ozols, R., Parmar, M. K. B., Pecorelli, S., Pfisterer, J., Poveda, A. M., Provencher, D. M., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G. J. S., Sagae, S., Stehman, F. B., Stuart, G. C. E., Trimble, E. L., Vasey, P. A., Vergote, I. B., Verheijen, R. H. M., and Wagner, U., 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)., Ann Oncol, vol. 16 Suppl 8, pp. viii7-viii12, 2005.
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.